![Mitchel Berger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mitchel Berger
Directeur/Membre du Conseil chez
POLARYX THERAPEUTICS, INC.
Profil
Mitchel Berger is currently the Director at the American Association of Neurological Surgeons.
Dr. Berger is also an Independent Director at Polaryx Therapeutics, Inc., starting in 2026.
Dr. Berger completed undergraduate education at Harvard College and graduate education at The University of Miami Leonard M.
Miller School of Medicine.
Postes actifs de Mitchel Berger
| Sociétés | Poste | Début |
|---|---|---|
| POLARYX THERAPEUTICS, INC. | Directeur/Membre du Conseil | 29/01/2026 |
American Association of Neurological Surgeons
 American Association of Neurological Surgeons Miscellaneous Commercial ServicesCommercial Services Operates association of neurological surgeons | Directeur/Membre du Conseil | - |
Formation de Mitchel Berger
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
24
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
American Association of Neurological Surgeons
American Association of Neurological Surgeons Miscellaneous Commercial ServicesCommercial Services Operates association of neurological surgeons | Commercial Services |
Harvard College
 Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Miami Leonard M. Miller School of Medicine
 The University of Miami Leonard M. Miller School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Polaryx Therapeutics, Inc.
 Polaryx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that engages in discovery, development and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders | Commercial Services |
